source
- Deerfield-backed Boulevard Bio raises $65 million and unveils three autoimmune drug candidatesBoulevard Bio, a New York‑based biotech focused on B‑cell biology, announced it has emerged from stealth with $65 million in financing from Deerfield Management. The funding supports the developmen…
- BioMarin halts development of BMN 401 after phase 3 missBioMarin Pharmaceutical announced it is ending all work on its experimental enzyme replacement therapy BMN 401 following a late‑stage trial that did not meet one of two primary goals in patients wi…